
AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …

AstraZeneca and its biologics R&D arm MedImmune have released a statement admitting that their fully human monoclonal antibody anifrolumab failed …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

